NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Independent reports  1  2  3  » 
found files: 47
»01/05/2007 [Independent reports]
Science Goes to China

An article in The Scientist magazine...   more»

»03/03/2007 [Independent reports]
Challenges Facing Chinese Domestic Pharmaceutical Industry

A Report by: Dominique Ding Professor Hauskrecht G400 Economic Consulting March 3rd, 2007...   more»

»26/05/2007 [Independent reports]
China, India ahead of S'pore in race for pharmaceutical investments: PwC

SINGAPORE: Even as the Government injects large doses of resources to grow the life sciences industry, Singapore is apparently not the top choice for the majority of drug firms looking for places to pump their money into. According to a survey by PricewaterhouseCoopers (PwC), "China and India head the list of target countries for expansion, with Singapore and South Korea next in the sights of multinational corporations (MNCs)"....   more»

»04/06/2007 [Independent reports]
Project Overview: Assessing GLP Compliance and Quality Practices in China

Taken from CHA's website...   more»

»09/08/2007 [Independent reports]
Asia Pacific to Replace United States and Europe as Pharmaceutical Industry Powerhouse, Finds Pricew

Asia Pacific to Replace United States and Europe as Pharmaceutical Industry Powerhouse, Finds PricewaterhouseCoopers Government Incentives Fuel Growth, But Intellectual Property Risk Remains a Concern...   more»

»30/08/2007 [Independent reports]
OECD: Further reforms would boost innovation in China

China needs a better return on its fast-rising investments in research and development (R&D) and higher education if it is to meet its goal of becoming an 'innovation-oriented' economy by 2020, according to a new report by the Organisation for Economic Co-operation and Development (OECD). Shortage of skilled science & technology workers expected...   more»

»03/09/2007 [Independent reports]
Lessons to be learnt about IP protection in China

China’s progress on the road to intellectual property rights is exemplified in pharmaceutical protection. This article describes a variety of laws and regulations that can be effectively used to protect pharmaceutical products in China....   more»

»03/09/2007 [Independent reports]
Preclinical outsourcing to Asia 'off the horizon'

A recent survey reveals that Western pharma companies are still shying away from outsourcing preclinical work to Asia. Meanwhile, Covance and Charles River clearly dominate this niche industry sector....   more»

»16/11/2007 [Independent reports]
China Expanding Bioresearch Activities

Questions Remain, However, on Quality, Regulatory, and Animal-welfare Concerns China plans to signficantly boost its research efforts in biotechnology, according to its Minister of Science and Technology. “Our goal is to turn China into a major player in the biological industry by 2020,” said Wan Gang, speaking at an international conference on biological economy in Tianjin in June. He predicted a total output value for the industry of 2.5 to 3 trillion yuan ($334 to $400 billion) by 2020....   more»

»14/01/2008 [Independent reports]
Review of China Biotech Industry

China biotech/health care investing grew 19% in Q3 to $50 million, though it still lagged by several orders of magnitude the $2 billion invested into biopharma in the U.S. Angel biomedical investing in the US added almost $2 billion more, but China angel investors put only a fraction of the $50 billion to work in very early stage companies. The situation is improving because, unlike some years back, young China biomedical companies have access to some capital. Still, the industry could benefit from more. Addressing that deficiency was part of the reason for the ChinaBio Investor Forum, which provided an opportunity for fifteen young companies to present their stories to the assembled venture capitalists. In Keynote Addresses and panel presentations at the Forum, executives, venture capitalists and lawyers dispensed their thoughts on what young China biomedical enterprises need to do to thrive in today’s environment....   more»

»13/03/2008 [Independent reports]
CROs bring innovation into Chinese pharmaceutical industry

Most of the big pharmaceutical firms and their products are well known to most people. Less well-known are the contract research organisations, known as CROs, which are increasingly important in the drug development process. Pharmaceutical companies outsource research to CROs, who can help them develop drugs faster and cheaper...   more»

»12/03/2008 [Independent reports]
Why Does Big Pharma come to China

China is on the minds and on the lips of the CEOs of the large multi-national pharmaceutical companies, commonly referred to as 'Big Pharma'. An improved regulatory environment, coupled with burgeoning Chinese pharmaceutical industry are bringing innovation to China....   more»

»07/04/2008 [Independent reports]
China's Rising Inflation Will Spread to Goods and Services by: Michael Pettis

ICBC, one of China’s Big Four commercial banks, released a report yesterday forecasting year on year CPI inflation in March to be 8.2%. This may seem like a big improvement over February’s 8.7% inflation number, but it actually represents a significant deterioration if ICBC turns out to be right because it will nonetheless represent a big jump over the more “normal” December and January numbers (6.5% and 7.1% respectively. February was a particularly bad month because the combined effect of the freak January storms and the Spring Festival had inflation shoot up in February by an annualized 35%. 8.2% year on year in March implies a month-on-month decline in the CPI index of about 0.8%, which after January’s and February’s 1.3% and 2.5% increases would imply that annualized inflation in the first quarter of 2008 will have just exceeded 12.5%. I don’t have the facilities to generate my own independent projection of monthly inflation, but ICBC’s projections are in line with some of the other projections I have seen and have come to trust. At that rate we can expect the headline year-on year CPI inflation number significantly to exceed 10% by May, which I think is a safe bet, although some analysts, for example those at ANZ, disagree – they think February’s number represents a peak for year-on-year inflation....   more»

»08/04/2008 [Independent reports]
Downturn in share prices don't hinder US/China Bio progress

With the first quarter of 2008 officially history, the news for US-listed China biomedical companies was not good: a loss of 27% in the ChinaBio Index . That put the CBI in between the benign loss (relatively speaking) of 14% for Nasdaq-listed stocks and a more major decline of 34% for the Shanghai Composite. As one of old stock market bromides says, stocks will do what they will do. But the downturn in stock prices hasn’t seemed to have much effect on China’s biomedical enterprises, which produced a heavier than usual news flow during the last week. CROs in particular were making deals. Commonwealth Biotechnologies, Inc. formed a China-based joint venture with Venturepharm Laboratories Ltd. [HKEX: 8225] . CBI, with headquarters in San Diego and facilities in Richmond, Melbourne and the UK, will use the JV to extend its service offerings to include contract manufacturing and clinical trials. Venturepharm, based in Beijing, will buy a block of stock in Commonwealth that comprises 39% of CBI’s outstanding shares, worth almost $6 million. Two other CROs, both based in the US but with labs in Asia, also formed a strategic alliance. Chemizon, a division of Optomagic, participated in Crown Bioscience’s Series B round of financing, as part of the alliance . Chemizon, headquartered in Longmont, CO, has labs in South Korea and Beijing. Chemizon is publicly traded in Korea, following a reverse merger with Optomagic. Crown Bioscience is based in Santa Clara, CA. It has labs in Beijing and Carmel, IN. Crown also has established a strategic alliance with Shanghai Tigermed Consulting, Inc., a clinical trial CRO dedicated to oncology...   more»

»08/05/2008 [Independent reports]
China's preclinical services scene evolving outwards

China's preclinical services providers are beginning to carve a nicehe for themselves on the global stage, buoyed by the growth of the domestic market. China's pharmaceutical industry, which holds vast potential but remains largely untapped, is finally waking up, growing 30 per cent a year between 2000 and 2005 to reach $3bn, compared with a 19 per cent annual growth rate for the pharmaceutical industry as a whole. According to a recent article in Nature Biotechnology, titled: "Chinese health biotech and the billion-patient market", as the domestic market continues to evolve, several Chinese companies that were founded with a pure research and development (R&D) business plan have recognised that to stay afloat they needed to adopt a new plan, one that would offset risks and costs and increase in-house capabilities. Hence the country's preclinical outsourcing industry was born. Many of these companies are now relying on contract services to generate revenues and remain competitive. The services they now offer range from early-stage research and preclinical development, to the clinical services and manufacturing aspect of the business also. WuXi PharmaTech, ShangPharma, Shenzhen Chipscreen Biosciences, HD Biosciences, CapitalBio, Fudan-Yueda Bio-Tech and SinoGenoMax are among the dominant contract research organisations (CROs) that have sprung up over the years. As firms such as these have gained experience they are now drawing interest form international firms who are eyeing China's cost-efficiency of developing drugs compared with the west, resulting from the low-cost scientific talent, clinical trials and raw materials available in the country (with a lowest estimate of 10 per cent of the cost of similar expertise in the US). Now these Chinese services firms are beginning to take their businesses a step further - having gained the world's attention, they are recognising that their experiences with domestic regulatory agencies and markets are valuable to international clients, and they are using this knowledge in their business plans, according to the Nature article. Assistance in drug registration with Chinese regulatory agencies, such as those offered by Shanghai Genomics; and market consultation and clinical evaluations according to Chinese State Food and Drug Administration (SFDA) requirements as offered by Beijing Wantai are examples of expanding realms of service. China's largest preclinical services provider, WuXi PharmaTech, is at the forefront of this movement, being one of the first Chinese companies to market itself internationally as a pure service company. With over 1,000 employees, it is one of the country's largest biotech firms and provides services to support new drug discovery and the chemical development of new drug candidates. The company is in the midst of expanding its capabilities into preclinical toxicity, animal studies, bioassays and plant formulations, with the aim of becoming a fully integrated services company. According to the Nature article, WuXi PharmaTech's chairman and CEO, Ge Li, credits the company's success to an innovative approach both to operations and project management and to diligent protection of its clients' intellectual property (IP). Ensuring protection of clients' IP "is the lifeblood for a company like ours", he said. Meanwhile, international partnerships for innovation are also on the rise in China, with foreign biotechs increasingly forging new alliances with Chinese services firms. In January this year, US-based MPI Research and China's Shanghai Medicilon formed a preclinical services joint venture in China and in February, Europe's Novasecta formed an alliance with Chinese CROs Sundia Meditech and HD BioSciences to provide their R&D services to European mid-sized biopharma firms. Alongside this, the Chinese government is strongly encouraging foreign companies to develop their products in the country. In addition, investment in Chinese CROs by foreign firms is also on the rise, as witnessed by an increasing incidence of such deals over the past couple of years. For example, in January, China's NovaMed Pharmaceuticals secured $13.8m in Series B Funding from international investment firms Fidelity Asia Ventures and Fidelity Biosciences, and in in November 2007, China's second largest CRO ShangPharma attracted $30m from US private investment firm TPG....   more»

»27/05/2008 [Independent reports]
Ernst & Young reports record deals, smaller losses for biotech industry

Ernst & Young has released its annual report, Beyond Borders: Global Biotechnology Report 2008, which notes record high levels of venture capital in 2007 at $7.5 billion in the U.S. and $60 billion in new deals. In addition, globally the industry moved closer to profitability as it pruned its losses from $7.4 billion in 2006 to $2.7 billion in 2007. In the United States, according to the report, biotech came closer to overall profitability as an industry than in any previous year. The report mentions potential for changes in current trends, including a push for personalized medicine that will affect the current drug market; pharma companies collaborating with biotech firms; and companies embracing globalization by working with other markets. In Europe, the biotech industry's revenue decreased, while products awaiting clinical trial increased. Australia and China saw an increase in IPOs worth $750 million....   more»

»22/06/2008 [Independent reports]
Doing Business in Asia – Is China Becoming Too Expensive

We are no longer coming to China for cost savings, we are coming because the Chinese work hard and they value education. We no longer find that in the US.” An unnamed chief scientific officer from an international big pharma, quoted by Charles Hsu of Bay City Capital at the Opportunities for Collaborations and Investment Panel Presentation. At the 2008 BIO International Convention, a panel of industry representatives, all of whom are involved in biopharma development in the US and Asia, discussed the merits and problems inherent in doing biopharma business in various Asian countries. The discussion was unusual because, unlike most such forums, all Asian countries were discussed, with a special focus on the major sites – China, India, Korea and Japan. Ian Wisenberg (BIOCOM) introduced the discussion by stating it would be in the form of a workshop, that the participants did not have all the answers. As they answered questions, the participants articulated their insights on the countries in which they work. One of the themes that kept cropping up was how much has changed, particularly in China, in a very short time. Because the changes have been so rapid, costs have risen to the point where the cost advantage of doing business in China is being eroded....   more»

»21/06/2008 [Independent reports]
China Fuel Prices in Surprise Rise by Michael Pettis

I was going to write about speculative inflows and their impact on Chinese monetary policy, but a lot has been happening – and just in the middle of my week-long trip out of China – so I will postpone that discussion for Monday. On Thursday, as almost everyone knows by now, just after the market closed Chinese authorities announced that were allowing fuel and energy prices to rise – fuel by nearly 18%. This came as something of a shock to everyone because it was widely believed that although fuel-related pressures were becoming intense, nothing would be done before the Olympics because of the socially disruptive impact a price hike might have – not to mention the worries about allowing inflationary expectations to grow. Aside from showing how little faith we should place on expert consensus, and that the embedded wisdom that nothing bad can possibly be allowed to happen before the Olympics is an exaggeration, there are at least two interpretations we might place on the timing: 1. The authorities were so comfortable with the May inflation report that they were not as frightened as many had assumed of the inflationary impact on CPI of a price rise, and decided that they can now begin allowing price freezes to unwind. 2. The fuel-related losses and shortages had become so severe that it was becoming too dangerous to wait. My suspicion is that the latter was more important a reason. I have been hearing reports from friends and readers around China that shortages were becoming a far more serious problem than most of us realize. I will discuss some of these reports and comments in a later entry, but it may be that it was getting harder and harder for the authorities to postpone some sort of price rise. The relatively benign May CPI numbers may have created enough comfort for the authorities, especially if they were eagerly hoping for good news and willing to interpret any good news in the most positive light, that they were able to arrive at the necessary consensus. If I am wrong, and it was the resurgence in confidence that inflation is being beaten that propelled the hike in fuel and energy prices, we should probably begin to see price freezes on food relaxed quickly. At any rate the impact on the stock market of the hike in fuel and energy prices was quite predictable. Rising oil prices have been especially bad for the Shanghai market because, aside from all the other negative economic consequences they have for most companies, they were especially bad for oil companies who had to sell rising amounts of imported oil at huge losses. When China made the announcement that it would let fuel prices rise, and oil immediately fell on international markets, it was almost a certainty that the market would rise. And they did. Not without a struggle at first, however. The market dropped 104 points in the first 30 minutes of trading, before staging a rally that took it up to 2902 by the end of the morning, after which it lost steam in the afternoon to close at 2832, up 3.01% for the day. I don’t expect this rally to continue, although a number of large banks and funds have moved China to overweight on the argument that the Shanghai market is oversold. Higher oil prices in China may be good for the oil companies, but I expect it is bad for everyone else, and after investors have had the weekend to think things over, I expect pessimism will return, unless international oil prices continue falling....   more»

»02/07/2008 [Independent reports]
China's consumer confidence index drops

China consumer confidence index dropped in the second quarter, reflecting an expected cool down in the country's economy. The index fell 0.7 percentage points from the previous quarter to 94.1, said the National Bureau of Statistics (NBS) on Wednesday. The index was also 2.7 percentage points lower than in the same period last year. The Index, which measures consumers' outlook toward employment, the economy, regular income, stock market and quality of life, was released following the disclosure of a slightly lower entrepreneurial confidence index and a lower business climate index, both year-on-year figures for the second quarter. China's business climate index dropped 8.6 points to 137.4 points from last year's second quarter, while the entrepreneurial confidence index dipped 8.3 points to 134.8 from the same period last year...   more»

»08/08/2008 [Independent reports]
Six Key Chinese Healthcare ADRs by: Tom Malthus

As an additional follow-up to my ADR series (see previous articles on energy sector ADRs and financial sector ADRS), I am going to take a look at the Chinese and Hong Kong healthcare sector. There are 6 key Chinese and Hong Kong ADRs within the GICS healthcare sector: Mindray Medical International (MR), Chine Medical Technologies (CMED), Wuxi PharmaTech (WX), Simcere Pharmaceutical (SCR), 3SBio (SSRX), and Tongjitang Chinese Medicines (TCM) Chinese & HK Helathcare Sector ADRs Source: Bloomberg (Closing prices 8/7)...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.